Pacgen to present at Biofinance 2007



    TSX-V: PGA

    VANCOUVER, April 17 /CNW/ - Pacgen Biopharmaceuticals Corporation
("Pacgen" or the "Company") (TSX-V: PGA) announces that Robert DuFresne,
President and CEO will be presenting at the BioFinance 2007 Conference,
Toronto, Ontario, on Wednesday April 25, 2007 at 3:30pm EDT.

    About Pacgen
    Pacgen is a life sciences company focused on the development of peptide
therapeutics for the treatment of infectious and inflammatory diseases. The
Company's lead product, PAC-113, is an antifungal in a phase Ib/IIa clinical
trial in the United States and South Africa. Preliminary efficacy data from
this study is expected during the second quarter of calendar year 2007. Pacgen
also plans to file investigational new drug application or clinical trial
application in North America in late 2007 for PAC-G31P which is currently
being investigated in pre-clinical studies for its potential to treat
inflammatory diseases such as acute respiratory distress syndrome. For
additional information, please visit www.pacgenbiopharm.com.

    NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS
    RELEASE. THE TSX VENTURE EXHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE
    ADEQUACY OR ACCURACY OF THIS RELASE.

    Forward looking Statements
    Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Pacgen's
current beliefs as well as assumptions made by and information currently
available to Pacgen and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Pacgen in its Final Prospectus dated November 28,
2006, actual events may differ materially from current expectations. Pacgen
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise. For all forward-looking statements, Pacgen claims the safe harbour
for forward-looking statements within the meaning of the Private Securities
Legislation Reform.

    %SEDAR: 00024179E




For further information:

For further information: Carol Shafer, Manager, Investor Relations,
Pacgen Biopharmaceuticals, Phone: (604) 436-4388,
Email:cshafer@pacgenbiopharm.com

Organization Profile

PACGEN BIOPHARMACEUTICALS CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890